Amyloidosis—a collection of rare, often under-recognized disorders characterized by the buildup of misfolded protein fibrils in organs and tissues—has long posed a formidable challenge to clinicians and patients alike. Until recently, treatment options were limited and largely supportive. However, ongoing advances in molecular biology, diagnostic precision, and drug development are transforming ..